AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: Phase I trial in Patients with Advanced Solid Tumors.
Siu LL, Postel-Vinay S, Villanueva-Vázquez R, de Velasco G, Castanon Alvarez E, Kyriakopoulos CE, Johnson M, Ouali K, McMorn S, Angell HK, Ng F, Saran S, Bayat M, Collins T, Roy A, Lambert AW, Cho S, Miller N, Petruzzelli M, Stone J, Massard C.
Siu LL, et al. Among authors: roy a.
Clin Cancer Res. 2025 Feb 12. doi: 10.1158/1078-0432.CCR-24-1818. Online ahead of print.
Clin Cancer Res. 2025.
PMID: 39937271